Research programme: kidney disorder therapeutics - Bayer/Vanderbilt University Medical Center

Drug Profile

Research programme: kidney disorder therapeutics - Bayer/Vanderbilt University Medical Center

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; Vanderbilt University Medical Center
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • Research Kidney disorders

Most Recent Events

  • 11 Sep 2017 Bayer and Vanderbilt University Medical Center agree to co-develop therapeutics for Kidney disorders
  • 11 Sep 2017 Research programme: kidney disorder therapeutics - Bayer/Vanderbilt University Medical Center is available for licensing as of 11 Sep 2017. https://www.bayer.com/
  • 11 Sep 2017 Early research in Kidney disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top